Streamline Global Patient Program Compliance with Zelthy

A global patient program monitoring platform is a centralized system that gives pharmaceutical compliance teams real-time visibility across all patient support programs operating in multiple countries, with multiple vendors, under different regulatory frameworks — from a single dashboard. It replaces the fragmented oversight model where each region reports through different systems, different formats, and different timelines, leaving global teams blind to compliance gaps until audit time.

Global pharmaceutical companies increasingly rely on Patient Support Programs (PSPs) to enhance access, adherence, and patient outcomes. Regulatory agencies are increasingly recognizing this shift — the FDA's Patient-Focused Drug Development initiative emphasizes incorporating patient experience data into both clinical development and the support infrastructure surrounding therapies.

The monitoring challenge is structural: a typical multi-country PSP involves dozens of vendors, call centres, and service providers, each with its own data systems and its own interpretation of global SOPs. Without a unified monitoring layer, compliance teams spend the majority of their time chasing static reports, cross-checking vendor submissions, and manually validating adherence to policy — work that is slow, expensive, and error-prone. This post examines the core challenges and how a centralized, AI-driven approach to PSP compliance monitoring addresses them.

Challenges in Monitoring Global Patient Support Programs

1. Fragmented Data Systems

Each region often uses different data storage and reporting systems—ranging from local CRMs to third-party vendor tools—resulting in multiple datalakes with no unified oversight. This fragmentation prevents a single view of patient interactions and compliance status.

2. Inconsistent Policy Enforcement

While global SOPs aligned with frameworks like ICH-GCP may exist, their local implementation can vary significantly. Regional vendors and internal teams may interpret policies differently, increasing the likelihood of deviations and compliance gaps.

3. Vendor and Stakeholder Complexity

Large-scale PSPs often involve dozens of vendors, call centers, and service providers, each managing their own processes. Without a unified monitoring layer, it becomes difficult to assess whether each stakeholder is operating in line with global standards.

This challenge is compounded by evolving regulatory expectations — the EMA's pharmacovigilance guidelines now require that marketing authorization holders ensure GDPR-compliant handling of personal data across all partner and vendor interactions, including patient support program operations.

4. High Manual Workloads

Compliance teams spend considerable time chasing static reports, reviewing vendor submissions, and cross-checking compliance against policy documents—an inefficient and error-prone process.

Zelthy’s Solution: A Centralized Compliance Monitoring Solution for PSPs

Zelthy’s Global Patient Program Monitoring Platform is designed to solve these enterprise challenges with a technology-first approach. It consolidates program data, digitizes policy frameworks, and enables real-time oversight of global PSP operations.

Key Features and Benefits

• Centralized Compliance Datalake: The platform ingests structured and unstructured data from all PSP sources into a secure, unified environment. This eliminates silos and enables global teams to access a consolidated view of all ongoing programs and stakeholders.
• Policy Management Engine: Global and local compliance policies can be uploaded and configured within the platform. Each program’s operational data is continuously validated against these policies, flagging potential deviations automatically.
• Real-Time Monitoring of Vendors and Regions: Zelthy offers dashboards that allow real-time tracking of vendor activities, patient interactions, and support workflows—enabling early detection of non-compliant actions.
• AI-Driven Compliance Workflows: AI models analyze data against the uploaded policy rules and trigger alerts when anomalies or deviations are detected. This significantly reduces manual review and increases monitoring coverage.
• Automated, Audit-Ready Reports: Generate customizable compliance and operations reports by geography, vendor, or therapeutic area—streamlining internal reviews and regulatory inspections.

The operational stakes are significant: the WHO estimates that medication adherence in chronic disease averages only 50% in developed countries, and fragmented PSP monitoring directly contributes to this gap by allowing compliance breakdowns to go undetected across vendor networks.

Why Global Pharma Companies Choose Zelthy

Pharmaceutical leaders choose Zelthy to streamline oversight across complex, multi-country patient support ecosystems. The platform offers:

• A unified system to manage PSPs run by diverse vendors across geographies. These monitoring capabilities sit on top of Zelthy's patient services platform, which handles the underlying operational workflows — enrollment, adherence tracking, call centre management, and therapy-specific engagement.
• Built-in policy enforcement aligned with HIPAA, GDPR, and market-specific regulations.
• Real-time alerts and AI-driven flagging of policy deviations to reduce compliance risk. PSP monitoring is one application of a broader capability; Zelthy's compliance and quality platform extends the same continuous monitoring approach to pharmacovigilance, promotional review, SOP management, and audit readiness.
• Automation that significantly cuts manual workload for compliance and operations teams.
• Proven success in accelerating program approvals, improving adherence, and reducing costs—as seen in deployments across Australia and APAC.

For instance, a top pharma in Australia reduced PSP approval times by 65% after migrating from paper-based workflows to Zelthy’s digital platform. Another oncology PSP achieved a 45% boost in adherence and a 60% faster enrollment process through the platform’s patient-centric modules.

Programs operating under Australia's Therapeutic Goods Administration (TGA) face particularly rigorous oversight for compassionate access and special access schemes, making the compliance efficiency gains especially significant.

These results highlight why pharma companies globally are turning to Zelthy to modernize compliance, improve program efficiency, and scale PSPs with confidence.

Read the full story of how a leading pharma boosted cancer therapy adherence by 45% in Australia using Zelthy's patient-centric modules.

Conclusion

As patient support programs continue to expand across borders, pharma companies need more than regional dashboards and vendor PDFs to manage compliance. They need a centralized, scalable platform that aligns with enterprise data governance standards and regulatory expectations.

Zelthy’s Global Patient Program Monitoring Platform delivers this capability, helping compliance and ethics leaders stay ahead of risk, improve transparency, and drive operational efficiency across PSP ecosystems.

Book a free demo to see how Zelthy can transform your global PSP monitoring into a streamlined, compliant, and data-driven operation. For more information, reach out to us at connect@zelthy.com or send us a direct message on LinkedIn.

Frequently Asked Questions

What challenges do global pharma companies face in monitoring PSP compliance?

Global PSP compliance monitoring faces four structural challenges: fragmented data systems where each region uses different CRMs and vendor tools with no unified view; inconsistent policy enforcement as local teams interpret global SOPs differently; vendor complexity when dozens of call centers and service providers operate independently; and high manual workloads as compliance teams chase static reports and cross-check submissions against policy documents without automation.

What is a centralized PSP compliance monitoring platform?

A centralized PSP compliance monitoring platform ingests structured and unstructured data from all patient support program vendors and regions into a unified, governed environment. It digitizes global and local compliance policies, validates operational data against those policies in real time, and generates automated alerts when deviations are detected. This replaces manual vendor report review with continuous, automated oversight — enabling compliance teams to monitor far more programs with the same resources.

How does AI improve PSP compliance monitoring?

AI compliance models analyze PSP operational data — patient interactions, vendor activities, support workflows — against configured policy rules and flag anomalies without requiring manual case-by-case review. This significantly increases monitoring coverage: whereas human reviewers can audit a sample of vendor submissions, AI models can evaluate all interactions continuously. AI-driven workflows also enable earlier detection of emerging compliance patterns before they become reportable violations or regulatory findings.

What regulations must global PSP compliance platforms address?

Global PSP platforms must simultaneously enforce HIPAA requirements for US patient data handling, GDPR data minimization and consent standards for EU patient interactions, and market-specific regulations from authorities such as PMDA (Japan), TGA (Australia), CDSCO (India), and ANVISA (Brazil). These frameworks impose different consent requirements, data retention periods, and cross-border transfer restrictions. A unified platform must maintain jurisdiction-specific rule sets while providing a consolidated compliance view for global ethics and compliance leadership.

What does an audit-ready PSP compliance report include?

An audit-ready PSP compliance report provides regulators or internal reviewers with a documented record of every patient interaction, vendor activity, policy validation event, and deviation flag within the program — organized by geography, vendor, therapeutic area, and time period. Reports must demonstrate consent traceability, adverse event capture and forwarding, role-based access enforcement, and policy adherence rates. Generating these reports in hours rather than weeks is a primary operational differentiator of automated compliance platforms versus manual review processes.

Why do multi-vendor PSP environments create compliance blind spots?

When each PSP vendor — hub services, specialty pharmacy, call center, nurse field services — manages its own data in its own system, no single entity has visibility into the complete patient journey or the cumulative compliance picture. A patient who reports an adverse event to a nurse vendor may not have that event captured in the specialty pharmacy's system, creating a pharmacovigilance reporting gap. Inconsistent KPI definitions across vendors also make it impossible to produce credible compliance metrics for regulatory submissions or internal governance.

How does real-time PSP monitoring reduce compliance risk?

Real-time monitoring enables proactive compliance management: deviations are detected as they occur rather than discovered during quarterly audits or regulatory inspections. Early detection allows compliance teams to investigate and remediate issues before they compound — for example, a vendor consistently miscapturing consent can be corrected before the error affects thousands of patient records. Real-time dashboards also provide the documented audit trail that demonstrates to regulators that the organization had effective controls in place, which significantly reduces penalty exposure even when violations occur.